Helixmith Co Ltd operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Helixmith Co Ltd with three other
pharmaceutical manufacturers in Asia:
Solasia Pharma KK
sales of 318.00 million Japanese Yen [US$2.92 million]
of which 100%
was Pharmaceutical busi),
Tego Science Inc
(7.85 billion Korean Won [US$6.59 million]
of which 96%
was Cell Therapy Products), and
(3.86 billion Korean Won [US$3.24 million]
of which 48%
was Finished Goods).
Helixmith Co Ltd reported sales of 5.28 billion Korean Won (US$4.43 million)
December of 2018.
increase of 67.2%
versus 2017, when the company's sales were 3.16 billion Korean Won.
Despite this increase, sales are still
below the level achieved in 2016, when Helixmith Co Ltd
reported sales of 6.84 billion Korean Won.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Helixmith Co Ltd had sales
of 5.75 billion Korean Won.